Should a drugmaker not have to pay punitive damages for product liability because such penalties encroach on the ability of the FDA to enforce its authority? This is the question that Novartis hopes the US Supreme Court will answer in its upcoming session, although whether the justices will agree to review the issue is unclear. A decision may be known next week.
Help employers find you! Check out all the jobs and post your resume.
